title: Prevention of type I diabetes with lymphotoxin in BB rats.
abstract: We previously reported that nonspecific immunomodulations with a streptococcal preparation (OK-432), an inducer of tumor necrosis factor (TNF), or with recombinant TNF prevented development of insulin-dependent diabetes mellitus (IDDM) in animal models (NOD mice and BB rats). Recently we have further reported that lymphotoxin (LT), a cytokine with functional and structural characteristics similar to those of TNF, also protected NOD mice from diabetes. In this study, we have extended our observation on the LT to BB rats. Male and female BB/Wor rats were treated intraperitoneally with recombinant human LT three times a week from 4 to 11 weeks of age. The cumulative incidence of diabetes by 14 weeks of age was 24/30 (80.0%) in nontreated control rats, whereas it was 10/26 (38.5% vs control, P < 0.01) and 4/29 (13.8% vs control, P < 0.0001) in the rats treated with 1 x 10(3) and 1 x 10(4) of LT, respectively. There was no significant difference in nonfasting blood glucose levels and body weights between nontreated control and LT-treated rats, which were nondiabetic. In the LT-treated rats, intensity of insulitis was significantly reduced in comparison with the nontreated rats. Concanavalin A-stimulated TNF/LT productivity of spleen cells was significantly lower in BB/Wor and BB/Sendai rats than in Wistar rats or other normal rat strains. On the other hand, there was no difference between BB/Sendai and Wistar rats in the in vivo TNF/LT productivity induced with LPS or with IFN-gamma plus LPS, and the TNF/LT productivity of these rats was lower on stimulation with LPS alone, but higher with IFN-gamma plus LPS than the other normal rats. These results indicate that treatment with LT, as well as TNF, modulated autoimmunity and prevented development of IDDM in BB/Wor rats which may be low producers of TNF/LT.
authors.affiliation: Third Department of Internal Medicine, Tohoku University School of Medicine, Miyagi, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: J
authors.initials: J
authors.lastname: Satoh
authors.forename: H
authors.initials: H
authors.lastname: Seino
authors.forename: X P
authors.initials: XP
authors.lastname: Zhu
authors.forename: M
authors.initials: M
authors.lastname: Sagara
authors.forename: T
authors.initials: T
authors.lastname: Masuda
authors.forename: T
authors.initials: T
authors.lastname: Toyota
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000517:prevention & control; D001835:Body Weight; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D005260:Female; D008233:Lymphotoxin-alpha / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D011913:Rats, Inbred BB / Q000502:physiology*; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
chemical_list: D008233:Lymphotoxin-alpha; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha